Pet Non-steroidal anti-inflammatory drugs (NSAIDs) are medicines that are widely used to relieve pain, reduce inflammation, and bring down a high temperature. They can relieve the pain caused by inflammation of the pet's knee joint.
The global Pet NSAIDs market was valued at US$ 35 million in 2023 and is anticipated to reach US$ 48 million by 2030, witnessing a CAGR of 4.1% during the forecast period 2024-2030.
Pet medical care is the second largest segment in pet industry. In the UK, annual spending on veterinary and other pet services has risen from 拢2.6bn in 2015 to 拢4bn in 2021, a 54% increase in just six years. According to Vetnosis, the value of the global animal health industry will increase by 12% to $38.3 billion in 2021. White Paper on China's Pet Healthy Consumption of JD shows that in 2023, there are 13.09 million pets entering middle age and old age. And pet aging is expected to be seen in the next few years. Changes in the age structure of pets will further bring about the development of the pet medical industry. According to the data of the 2022 China Pet Medical Industry White Paper, from the perspective of market size, the scale of China's pet medical market is about 楼67.5 billion, accounting for about 22.5% of the entire pet industry. From the perspective of hospital operation time, pet hospitals within 5 years accounted for about 73%. About 11% of the pet hospitals have been in operation for more than 10 years. From the perspective of hospital turnover, nearly 40% of the hospitals have increased their annual turnover year-on-year, and the growth rate is mainly within 46%.
This report aims to provide a comprehensive presentation of the global market for Pet NSAIDs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pet NSAIDs.
Report Scope
The Pet NSAIDs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pet NSAIDs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pet NSAIDs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Zoetis
Elanco
PREVICOX
Metacam
Chanelle Pharma
AVENTIX
Woodruff
KRKA UK Ltd
Dechra
Parnell
VetUK
Norbrook
Alivira Animal Health
Vedco Inc
Vethical
Vetoquinol
Pivetal
Segment by Type
Carprofen
Deracoxib
Firocoxib
Meloxicam
Segment by Application
Dog
Cat
Horse
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pet NSAIDs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pet NSAIDs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Pet NSAIDs Market Overview
1.1 Product Overview and Scope of Pet NSAIDs
1.2 Pet NSAIDs Segment by Type
1.2.1 Global Pet NSAIDs Market Value Comparison by Type (2024-2030)
1.2.2 Carprofen
1.2.3 Deracoxib
1.2.4 Firocoxib
1.2.5 Meloxicam
1.3 Pet NSAIDs Segment by Application
1.3.1 Global Pet NSAIDs Market Value by Application: (2024-2030)
1.3.2 Dog
1.3.3 Cat
1.3.4 Horse
1.3.5 Others
1.4 Global Pet NSAIDs Market Size Estimates and Forecasts
1.4.1 Global Pet NSAIDs Revenue 2019-2030
1.4.2 Global Pet NSAIDs Sales 2019-2030
1.4.3 Global Pet NSAIDs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Pet NSAIDs Market Competition by Manufacturers
2.1 Global Pet NSAIDs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Pet NSAIDs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Pet NSAIDs Average Price by Manufacturers (2019-2024)
2.4 Global Pet NSAIDs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Pet NSAIDs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Pet NSAIDs, Product Type & Application
2.7 Pet NSAIDs Market Competitive Situation and Trends
2.7.1 Pet NSAIDs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Pet NSAIDs Players Market Share by Revenue
2.7.3 Global Pet NSAIDs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Pet NSAIDs Retrospective Market Scenario by Region
3.1 Global Pet NSAIDs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Pet NSAIDs Global Pet NSAIDs Sales by Region: 2019-2030
3.2.1 Global Pet NSAIDs Sales by Region: 2019-2024
3.2.2 Global Pet NSAIDs Sales by Region: 2025-2030
3.3 Global Pet NSAIDs Global Pet NSAIDs Revenue by Region: 2019-2030
3.3.1 Global Pet NSAIDs Revenue by Region: 2019-2024
3.3.2 Global Pet NSAIDs Revenue by Region: 2025-2030
3.4 North America Pet NSAIDs Market Facts & Figures by Country
3.4.1 North America Pet NSAIDs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Pet NSAIDs Sales by Country (2019-2030)
3.4.3 North America Pet NSAIDs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Pet NSAIDs Market Facts & Figures by Country
3.5.1 Europe Pet NSAIDs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Pet NSAIDs Sales by Country (2019-2030)
3.5.3 Europe Pet NSAIDs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Pet NSAIDs Market Facts & Figures by Country
3.6.1 Asia Pacific Pet NSAIDs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Pet NSAIDs Sales by Country (2019-2030)
3.6.3 Asia Pacific Pet NSAIDs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Pet NSAIDs Market Facts & Figures by Country
3.7.1 Latin America Pet NSAIDs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Pet NSAIDs Sales by Country (2019-2030)
3.7.3 Latin America Pet NSAIDs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Pet NSAIDs Market Facts & Figures by Country
3.8.1 Middle East and Africa Pet NSAIDs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Pet NSAIDs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Pet NSAIDs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Pet NSAIDs Sales by Type (2019-2030)
4.1.1 Global Pet NSAIDs Sales by Type (2019-2024)
4.1.2 Global Pet NSAIDs Sales by Type (2025-2030)
4.1.3 Global Pet NSAIDs Sales Market Share by Type (2019-2030)
4.2 Global Pet NSAIDs Revenue by Type (2019-2030)
4.2.1 Global Pet NSAIDs Revenue by Type (2019-2024)
4.2.2 Global Pet NSAIDs Revenue by Type (2025-2030)
4.2.3 Global Pet NSAIDs Revenue Market Share by Type (2019-2030)
4.3 Global Pet NSAIDs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Pet NSAIDs Sales by Application (2019-2030)
5.1.1 Global Pet NSAIDs Sales by Application (2019-2024)
5.1.2 Global Pet NSAIDs Sales by Application (2025-2030)
5.1.3 Global Pet NSAIDs Sales Market Share by Application (2019-2030)
5.2 Global Pet NSAIDs Revenue by Application (2019-2030)
5.2.1 Global Pet NSAIDs Revenue by Application (2019-2024)
5.2.2 Global Pet NSAIDs Revenue by Application (2025-2030)
5.2.3 Global Pet NSAIDs Revenue Market Share by Application (2019-2030)
5.3 Global Pet NSAIDs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Zoetis
6.1.1 Zoetis Corporation Information
6.1.2 Zoetis Description and Business Overview
6.1.3 Zoetis Pet NSAIDs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Zoetis Pet NSAIDs Product Portfolio
6.1.5 Zoetis Recent Developments/Updates
6.2 Elanco
6.2.1 Elanco Corporation Information
6.2.2 Elanco Description and Business Overview
6.2.3 Elanco Pet NSAIDs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Elanco Pet NSAIDs Product Portfolio
6.2.5 Elanco Recent Developments/Updates
6.3 PREVICOX
6.3.1 PREVICOX Corporation Information
6.3.2 PREVICOX Description and Business Overview
6.3.3 PREVICOX Pet NSAIDs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 PREVICOX Pet NSAIDs Product Portfolio
6.3.5 PREVICOX Recent Developments/Updates
6.4 Metacam
6.4.1 Metacam Corporation Information
6.4.2 Metacam Description and Business Overview
6.4.3 Metacam Pet NSAIDs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Metacam Pet NSAIDs Product Portfolio
6.4.5 Metacam Recent Developments/Updates
6.5 Chanelle Pharma
6.5.1 Chanelle Pharma Corporation Information
6.5.2 Chanelle Pharma Description and Business Overview
6.5.3 Chanelle Pharma Pet NSAIDs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Chanelle Pharma Pet NSAIDs Product Portfolio
6.5.5 Chanelle Pharma Recent Developments/Updates
6.6 AVENTIX
6.6.1 AVENTIX Corporation Information
6.6.2 AVENTIX Description and Business Overview
6.6.3 AVENTIX Pet NSAIDs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 AVENTIX Pet NSAIDs Product Portfolio
6.6.5 AVENTIX Recent Developments/Updates
6.7 Woodruff
6.6.1 Woodruff Corporation Information
6.6.2 Woodruff Description and Business Overview
6.6.3 Woodruff Pet NSAIDs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Woodruff Pet NSAIDs Product Portfolio
6.7.5 Woodruff Recent Developments/Updates
6.8 KRKA UK Ltd
6.8.1 KRKA UK Ltd Corporation Information
6.8.2 KRKA UK Ltd Description and Business Overview
6.8.3 KRKA UK Ltd Pet NSAIDs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 KRKA UK Ltd Pet NSAIDs Product Portfolio
6.8.5 KRKA UK Ltd Recent Developments/Updates
6.9 Dechra
6.9.1 Dechra Corporation Information
6.9.2 Dechra Description and Business Overview
6.9.3 Dechra Pet NSAIDs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Dechra Pet NSAIDs Product Portfolio
6.9.5 Dechra Recent Developments/Updates
6.10 Parnell
6.10.1 Parnell Corporation Information
6.10.2 Parnell Description and Business Overview
6.10.3 Parnell Pet NSAIDs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Parnell Pet NSAIDs Product Portfolio
6.10.5 Parnell Recent Developments/Updates
6.11 VetUK
6.11.1 VetUK Corporation Information
6.11.2 VetUK Pet NSAIDs Description and Business Overview
6.11.3 VetUK Pet NSAIDs Sales, Revenue and Gross Margin (2019-2024)
6.11.4 VetUK Pet NSAIDs Product Portfolio
6.11.5 VetUK Recent Developments/Updates
6.12 Norbrook
6.12.1 Norbrook Corporation Information
6.12.2 Norbrook Pet NSAIDs Description and Business Overview
6.12.3 Norbrook Pet NSAIDs Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Norbrook Pet NSAIDs Product Portfolio
6.12.5 Norbrook Recent Developments/Updates
6.13 Alivira Animal Health
6.13.1 Alivira Animal Health Corporation Information
6.13.2 Alivira Animal Health Pet NSAIDs Description and Business Overview
6.13.3 Alivira Animal Health Pet NSAIDs Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Alivira Animal Health Pet NSAIDs Product Portfolio
6.13.5 Alivira Animal Health Recent Developments/Updates
6.14 Vedco Inc
6.14.1 Vedco Inc Corporation Information
6.14.2 Vedco Inc Pet NSAIDs Description and Business Overview
6.14.3 Vedco Inc Pet NSAIDs Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Vedco Inc Pet NSAIDs Product Portfolio
6.14.5 Vedco Inc Recent Developments/Updates
6.15 Vethical
6.15.1 Vethical Corporation Information
6.15.2 Vethical Pet NSAIDs Description and Business Overview
6.15.3 Vethical Pet NSAIDs Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Vethical Pet NSAIDs Product Portfolio
6.15.5 Vethical Recent Developments/Updates
6.16 Vetoquinol
6.16.1 Vetoquinol Corporation Information
6.16.2 Vetoquinol Pet NSAIDs Description and Business Overview
6.16.3 Vetoquinol Pet NSAIDs Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Vetoquinol Pet NSAIDs Product Portfolio
6.16.5 Vetoquinol Recent Developments/Updates
6.17 Pivetal
6.17.1 Pivetal Corporation Information
6.17.2 Pivetal Pet NSAIDs Description and Business Overview
6.17.3 Pivetal Pet NSAIDs Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Pivetal Pet NSAIDs Product Portfolio
6.17.5 Pivetal Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Pet NSAIDs Industry Chain Analysis
7.2 Pet NSAIDs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Pet NSAIDs Production Mode & Process
7.4 Pet NSAIDs Sales and Marketing
7.4.1 Pet NSAIDs Sales Channels
7.4.2 Pet NSAIDs Distributors
7.5 Pet NSAIDs Customers
8 Pet NSAIDs Market Dynamics
8.1 Pet NSAIDs Industry Trends
8.2 Pet NSAIDs Market Drivers
8.3 Pet NSAIDs Market Challenges
8.4 Pet NSAIDs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Zoetis
Elanco
PREVICOX
Metacam
Chanelle Pharma
AVENTIX
Woodruff
KRKA UK Ltd
Dechra
Parnell
VetUK
Norbrook
Alivira Animal Health
Vedco Inc
Vethical
Vetoquinol
Pivetal
听
听
*If Applicable.